Investor Presentation Q1-Q3 2020
38
Investor presentation First nine months of 2020
Novo Nordisk®
Diabetes volume growth remains solid with 4% growth in a large
USD 50 billion diabetes market
The number of treated patients¹ is expected to
grow by 4% annually towards 2026
206M
CAGR: +4%
ILLUSTRATIVE
The diabetes realised value² is expected to grow by
3% annually towards 2026
$
50bn
CAGR: +3%
.
ILLUSTRATIVE
Key trends in diabetes
Innovation focused on oral GLP-1
and combinations
Biosimilar competition and loss
of exclusivity
Diabetes technology with digital
health
2019
2026
Other OAD
DPP-4i
SGLT-2i
2019
GLP-1
Insulin
•
2026
.
Patients outcome beyond
glucose control
Evolving payer dynamics and
market access hurdles
Access and affordability of
medicine
1 Patient data: Novo Nordisk forecast; 2 Value data: 2018 data based on company reported sales and 2025 is based on a projection of diabetes market realised sales;
Note: GLP-1+basal insulin combination sales are included in insulin; Other OAD includes metformin, SU and TZDs; DPP-4i+SGLT-2i products are included in the SGLT-2i group. Growth rates are compound annual growth rates (CAGR).View entire presentation